Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Common Equity (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Common Equity readings, the most recent being $7.4 million for Q4 2024.

  • On a quarterly basis, Common Equity rose 295.09% to $7.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.4 million, a 295.09% increase, with the full-year FY2024 number at $7.4 million, up 295.09% from a year prior.
  • Common Equity hit $7.4 million in Q4 2024 for Unicycive Therapeutics, up from -$27.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $16.5 million in Q4 2021 to a low of -$27.8 million in Q3 2024.
  • Median Common Equity over the past 4 years was -$466000.0 (2022), compared with a mean of -$3.9 million.
  • The widest YoY moves for Common Equity: up 295.09% in 2024, down 911.01% in 2024.
  • Unicycive Therapeutics' Common Equity stood at $16.5 million in 2021, then crashed by 102.83% to -$466000.0 in 2022, then plummeted by 717.38% to -$3.8 million in 2023, then soared by 295.09% to $7.4 million in 2024.
  • The last three reported values for Common Equity were $7.4 million (Q4 2024), -$27.8 million (Q3 2024), and -$14.8 million (Q2 2024) per Business Quant data.